Post Transplant Study

Amgen

Status: Completed

Conditions: Hyperparathyroidism; Kidney Tansplant; Secondary Hyperparathyroidism

Treatments: Drug: Sensipar after Post Transplant

Study type: Observational

Funder types: Industry

Identifiers

NCT00395902

20040261

2004261

Details and patient eligibility

About

Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults >= 18 years old
• Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion criteria

• Subjects who received Sensipar before undergoing a kidney transplant
• Subjects receiving dialysis post-transplant